Positron Emission Tomography (PET) is a nuclear medicine modality allowing molecular and functional imaging. Hybrid systems, i.e. PET/CT, consist of a PET tomograph equipped with a CT (Computed Tomography) scan and allow simultaneous acquisition of emission (PET) and transmission (CT) images, in order to obtain fused images. PET is very useful in the diagnosis of brain primitive and secondary tumours, particularly in the detection of recurrence or progression of disease, in guiding biopsy and in radiotherapy treatment planning. 18F-Fluoro-deoxyglucose ( 18FDG), a glucose analogue using glycolitic pathways is the most widely used radiopharmaceutical, although in brain imaging many other more selective radiotracers are of great interest, such as radiolabelled Choline and Methionine analogues, 18F-Fluoro-ethyl- thyrosine, 18F-Fluoromisonidazolo. Finally future promising perspectives are represented by the recent development of PET/MR hybrid systems consisting of a PET scanner and a Magnetic Resonance (MR) tomograph to obtain fused images. These systems will be of great clinical role in the study of brain and particularly of brain tumours, allowing to precisely localize the site of a radiopharmaceutical neoplastic uptake.
Imaging molecolare PET (Tomografia ad emissione di Positroni) nello studio dei tumori cerebrali
PALUMBO, Barbara;TRANFAGLIA, CRISTINA;CARDINALI, LAURA;PALUMBO, Renato
2009
Abstract
Positron Emission Tomography (PET) is a nuclear medicine modality allowing molecular and functional imaging. Hybrid systems, i.e. PET/CT, consist of a PET tomograph equipped with a CT (Computed Tomography) scan and allow simultaneous acquisition of emission (PET) and transmission (CT) images, in order to obtain fused images. PET is very useful in the diagnosis of brain primitive and secondary tumours, particularly in the detection of recurrence or progression of disease, in guiding biopsy and in radiotherapy treatment planning. 18F-Fluoro-deoxyglucose ( 18FDG), a glucose analogue using glycolitic pathways is the most widely used radiopharmaceutical, although in brain imaging many other more selective radiotracers are of great interest, such as radiolabelled Choline and Methionine analogues, 18F-Fluoro-ethyl- thyrosine, 18F-Fluoromisonidazolo. Finally future promising perspectives are represented by the recent development of PET/MR hybrid systems consisting of a PET scanner and a Magnetic Resonance (MR) tomograph to obtain fused images. These systems will be of great clinical role in the study of brain and particularly of brain tumours, allowing to precisely localize the site of a radiopharmaceutical neoplastic uptake.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
